Estimates Revisions Glenmark Pharmaceuticals Limited Bombay S.E.
Stocks
GLENMARK
INE935A01035
Pharmaceuticals
|
Market Closed -
Bombay S.E.
06:02:32 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 2,288.95 INR | +0.32% |
|
-2.01% | +12.43% |
| 09-11 | Glenmark Pharmaceuticals Limited Proposes Dividend for the Year Ended 31 March 2026 | CI |
| 09-07 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Glenmark Pharmaceuticals Limited(GLENMARK)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Glenmark Pharmaceuticals Limited(GLENMARK)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Glenmark Pharmaceuticals Limited(GLENMARK)
EBIT
Dividend / Share (DPS)
Data source:
Glenmark Pharmaceuticals Limited(GLENMARK)
Cash or Net Debt
Select your edition
All financial news and data tailored to specific country editions
